Janus kinase inhibitors: jackpot or potluck?
نویسندگان
چکیده
منابع مشابه
Janus kinase inhibitors: jackpot or potluck?
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors. In one of the great victories of translational research in recent times, the first smallmolecule Janus kinase inhibitor ruxolitinib entered a phase I trial in 2007. With the approval of ruxolitinib by the US...
متن کاملAdvances in the Inhibitors of Janus Kinase
In recent years, for the lesion site, studies at the molecular level of drugs targeting protein molecules has been a major research method for exploiting new, high-efficiency drugs with low toxicity [1]. Janus kinases (JAKs) are important signal transducers of many cytokines, growth factors and interferon. In recent years, it has been found in cancer cells and cells transfected with oncogenes t...
متن کاملJAK 3 ( janus kinase 3 or just another kinase 3 )
JAK3 is expressed in 12 normal human tissues (bone marrow, spleen, thymus, brain, spinal cord, heart, skeletal muscle, liver, pancreas, prostate, kidney, and lung). JAK3S is more commonly seen in hematopoietic cells, whereas JAK3B and JAK3M are detected in cells of hematopoietic or epithelial origin. Localisation Intracellular, membrane-associated through association with interleukin (IL) recep...
متن کاملTranslational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
Alopecia areata (AA) is an autoimmune disease due to T cell attack of observation made in a special patient is complemented with mechanisthe hair follicles and breakdown of their immune privilege resulting in transient non-scarring hair loss which may last from weeks to decades and which presents an enormous psychological burden. As so far no FDA approved successful treatments for AA are availa...
متن کاملThe Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract. Current treatments are not universally effective or, in the case of therapeutic antibodies, are hampered by immune responses. Janus kinase inhibitors are orally delivered small molecules that target cytokine signall...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Reviews
سال: 2012
ISSN: 1970-5565,1970-5557
DOI: 10.4081/oncol.2012.e13